Caricamento...

Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer

Pembrolizumab, or anti-programmed death receptor 1 antibody, is an immune checkpoint inhibitor that can cause immune-related adverse events. We herein report for the first time the progression of hypopituitarism and hypothyroidism after treatment with pembrolizumab in a patient with adrenal metastas...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Intern Med
Autori principali: Yamagata, Satoshi, Kageyama, Kazunori, Takayasu, Shinobu, Asari, Yuko, Makita, Koshi, Terui, Ken, Daimon, Makoto
Natura: Artigo
Lingua:Inglês
Pubblicazione: The Japanese Society of Internal Medicine 2019
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6949454/
https://ncbi.nlm.nih.gov/pubmed/31462588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.3008-19
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !